The Cooper Companies, Inc. Common Stock (COO) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of sp...
The Cooper Companies, Inc. Common Stock's revenue increased 5.1% year over year, from $3.90B to $4.09B.
Net income decreased 4.4% over the same period, from $392.3M to $374.9M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 108% in total.
Total debt remained relatively stable at $2.51B.
The debt-to-equity ratio stands at 0.30, indicating a moderate leverage profile.
Operating cash flow grew 12.2% to $796.1M.
The Cooper Companies, Inc. Common Stock maintains a moderate net profit margin of 9.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2024 | $931.6M-65.1% | $81.2M | $623.8M | $153.1M | $122.7M | $12.03B | $2.77B | $7.70B |
| Q2 FY2024 | $1.87B+101.2% | $170.1M | $1.25B | $314.8M | $233.7M | $12.05B | $2.71B | $7.80B |
| Q3 FY2024 | $2.88B+53.5% | $274.8M | $1.92B | $507.3M | $441.2M | $12.11B | $2.63B | $7.92B |
| Q1 FY2025 | $964.7M-66.5% | $104.3M | $660.2M | $182.0M | $190.6M | $12.22B | $2.54B | $8.13B |
| Q2 FY2025 | $1.97B+103.9% | $192.0M | $1.34B | $366.8M | $286.8M | $12.41B | $2.59B | $8.29B |
| Q3 FY2025 | $3.03B+53.9% | $290.3M | $2.03B | $542.5M | $548.2M | $12.38B | $2.48B | $8.35B |
| Q1 FY2026 | $1.02B-66.2% | $130.8M | $695.2M | $212.8M | $260.9M | $12.42B | $2.50B | $8.36B |
| Q2 FY2026 | $2.11B+105.6% | $52.9M | $1.43B | $181.8M | $443.7M | $12.48B | $2.46B | $8.24B |